공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

척수 손상 : 파이프라인 리뷰

Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 229793
페이지 정보 영문 296 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


척수 손상 : 파이프라인 리뷰 Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 296 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

척수 손상은 척수가 신체적 외상을 받은 것으로 정의되며, 운동 기능 및 감각을 상실하거나 장애가 남습니다. 일반적으로 신체적 외상 및 질환(횡단성 척수염, 폴리오, 척추 파열, 프리드리히 운동실조증)에 의해 발생합니다. 사고 후에 나타나는 이 질환의 급성 징후는 극심한 등의 통증, 목 및 머리 또는 등의 압박감, 신체 일부의 힘이 빠지거나 감각 상실, 손, 손가락, 발, 발가락의 저림 및 감각 상실, 방광 및 장의 제어능력 상실, 균형을 잡고 보행하는 것이 곤란해짐, 사고 후 호흡 장애 발생, 목 및 등의 변형 등입니다.

척수 손상(Spinal Cord Injury) 치료제 개발 파이프라인의 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

척수 손상 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 개요

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

LSH 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Spinal Cord Injury, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Target, 2021 (Contd..1)
  • uNumber of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Spinal Cord Injury - Pipeline by 9 Meters Biopharma Inc, 2021
  • Spinal Cord Injury - Pipeline by AbbVie Inc, 2021
  • Spinal Cord Injury - Pipeline by Algiax Pharmaceuticals GmbH, 2021
  • Spinal Cord Injury - Pipeline by Angion Biomedica Corp, 2021
  • Spinal Cord Injury - Pipeline by Aposcience AG, 2021
  • Spinal Cord Injury - Pipeline by Athersys Inc, 2021
  • Spinal Cord Injury - Pipeline by Axoltis Pharma SAS, 2021
  • Spinal Cord Injury - Pipeline by Axoneural Therapeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by AXONIS Therapeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by BioAxone BioSciences Inc, 2021
  • Spinal Cord Injury - Pipeline by Cellatoz Therapeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by CellCure, 2021
  • Spinal Cord Injury - Pipeline by CSL Ltd, 2021
  • Spinal Cord Injury - Pipeline by CSPC Pharmaceutical Group Ltd, 2021
  • Spinal Cord Injury - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
  • Spinal Cord Injury - Pipeline by DeckTherapeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by EUSOL Biotech Co Ltd, 2021
  • Spinal Cord Injury - Pipeline by GABA Therapeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by Gene Therapy Research Institution Co Ltd, 2021
  • Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals LLC, 2021
  • Spinal Cord Injury - Pipeline by GNT Pharma Co Ltd, 2021
  • Spinal Cord Injury - Pipeline by Helixmith Co Ltd, 2021
  • Spinal Cord Injury - Pipeline by Hemostemix Inc, 2021
  • Spinal Cord Injury - Pipeline by Hibernaid Inc, 2021
  • Spinal Cord Injury - Pipeline by Histocell SL, 2021
  • Spinal Cord Injury - Pipeline by Hope Biosciences LLC, 2021
  • Spinal Cord Injury - Pipeline by Hopstem Biotechnology LLC, 2021
  • Spinal Cord Injury - Pipeline by iCELL Biotechnology Co Ltd, 2021
  • Spinal Cord Injury - Pipeline by Jazz Pharmaceuticals Plc, 2021
  • Spinal Cord Injury - Pipeline by Karyopharm Therapeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by Kidswell Bio Corp, 2021
  • Spinal Cord Injury - Pipeline by Kringle Pharma Inc, 2021
  • Spinal Cord Injury - Pipeline by Lineage Cell Therapeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by Locate Bio Ltd, 2021
  • Spinal Cord Injury - Pipeline by Mapreg SAS, 2021
  • Spinal Cord Injury - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
  • Spinal Cord Injury - Pipeline by NervGen Pharma Corp, 2021
  • Spinal Cord Injury - Pipeline by NeuExcell Therapeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by Neuroplast BV, 2021
  • Spinal Cord Injury - Pipeline by New World Laboratories Inc, 2021
  • Spinal Cord Injury - Pipeline by Novago Therapeutics AG, 2021
  • Spinal Cord Injury - Pipeline by Novartis AG, 2021
  • Spinal Cord Injury - Pipeline by Novoron Bioscience Inc, 2021
  • Spinal Cord Injury - Pipeline by NuNerve Pty Ltd, 2021
  • Spinal Cord Injury - Pipeline by Oligogen Inc, 2021
  • Spinal Cord Injury - Pipeline by Palisade Bio, Inc, 2021
  • Spinal Cord Injury - Pipeline by PharmatrophiX Inc, 2021
  • Spinal Cord Injury - Pipeline by Pharmazz Inc, 2021
  • Spinal Cord Injury - Pipeline by Q Therapeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by Radikal Therapeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by ReNetX Bio, 2021
  • Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc, 2021
  • Spinal Cord Injury - Pipeline by S.Biomedics Co Ltd, 2021
  • Spinal Cord Injury - Pipeline by SanBio Co Ltd, 2021
  • Spinal Cord Injury - Pipeline by StemCyte Inc, 2021
  • Spinal Cord Injury - Pipeline by Stemedica Cell Technologies Inc, 2021
  • Spinal Cord Injury - Pipeline by Stemmatters Biotecnologia e Medicina Regenerativa SA, 2021
  • Spinal Cord Injury - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
  • Spinal Cord Injury - Pipeline by TechnoPhage SA, 2021
  • Spinal Cord Injury - Pipeline by Truvitech LLC, 2021
  • Spinal Cord Injury - Pipeline by Tumorend LLC, 2021
  • Spinal Cord Injury - Pipeline by VersaPeutics Inc, 2021
  • Spinal Cord Injury - Pipeline by Xcelthera INC, 2021
  • Spinal Cord Injury - Pipeline by ZyVersa Therapeutics Inc, 2021
  • Spinal Cord Injury - Dormant Projects, 2021
  • Spinal Cord Injury - Dormant Projects, 2021 (Contd..1)
  • Spinal Cord Injury - Dormant Projects, 2021 (Contd..2)
  • Spinal Cord Injury - Dormant Projects, 2021 (Contd..3)
  • Spinal Cord Injury - Dormant Projects, 2021 (Contd..4)
  • Spinal Cord Injury - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Spinal Cord Injury, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Drugs In Development, 2021, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 9, 12, 1, 40 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 12 molecules, respectively.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Spinal Cord Injury - Overview
  • Spinal Cord Injury - Therapeutics Development
  • Spinal Cord Injury - Therapeutics Assessment
  • Spinal Cord Injury - Companies Involved in Therapeutics Development
  • Spinal Cord Injury - Drug Profiles
  • Spinal Cord Injury - Dormant Projects
  • Spinal Cord Injury - Discontinued Products
  • Spinal Cord Injury - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q